{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T01:23:04Z","timestamp":1794446584856,"version":"4.9.1"},"reference-count":29,"publisher":"American Association for Cancer Research (AACR)","issue":"20","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Osteoclasts mediate bone destruction in breast cancer skeletal metastases. Cathepsin K is a proteinase that is secreted by osteoclasts and degrades bone. Here, immunohistochemistry revealed that cathepsin K was expressed not only by osteoclasts but also by breast cancer cells that metastasize to bone. Following intratibial injection with cathepsin K\u2013expressing human BT474 breast cancer cells, tumor-bearing mice treated with a clinical dosing regimen of cathepsin K inhibitor (CKI; 50 mg\/kg, twice daily) had osteolytic lesions that were 79% smaller than those of tumor-bearing mice treated with the vehicle. The effect of CKI was also studied in a mouse model in which the i.v. inoculation of human B02 breast cancer cells expressing cathepsin K leads to bone metastasis formation. Drug administration was started before (preventive protocol) or after (treatment protocol) the occurrence of osteolytic lesions. In treatment protocols, CKI (50 mg\/kg, twice daily) or a single clinical dose of 100 \u03bcg\/kg zoledronic acid (osteoclast inhibitor) reduced the progression of osteolytic lesions by 59% to 66%. CKI therapy also reduced skeletal tumor burden by 62% compared with vehicle, whereas zoledronic acid did not decrease the tumor burden. The efficacy of CKI at inhibiting skeletal tumor burden was similar in the treatment and preventive protocols. By contrast, CKI did not block the growth of s.c. B02 tumor xenografts in animals. Thus, CKI may render the bone a less favorable microenvironment for tumor growth by inhibiting bone resorption. These findings raise the possibility that cathepsin K could be a therapeutic target for the treatment of bone metastases. [Cancer Res 2007;67(20):9894\u2013902]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-3940","type":"journal-article","created":{"date-parts":[[2007,10,17]],"date-time":"2007-10-17T17:39:01Z","timestamp":1192642741000},"page":"9894-9902","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":183,"title":["A Cathepsin K Inhibitor Reduces Breast Cancer\u2013Induced Osteolysis and Skeletal Tumor Burden"],"prefix":"10.1158","volume":"67","author":[{"given":"Ce\u0301line","family":"Le Gall","sequence":"first","affiliation":[{"name":"1Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale, UMR 664, IFR62, Lyon, France;"},{"name":"2Universite\u0301 Claude Bernard Lyon 1, Villeurbanne, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akeila","family":"Bellahce\u0300ne","sequence":"additional","affiliation":[{"name":"3Metastasis Research Laboratory, University of Lie\u0300ge, Lie\u0300ge, Belgium; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Bonnelye","sequence":"additional","affiliation":[{"name":"1Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale, UMR 664, IFR62, Lyon, France;"},{"name":"2Universite\u0301 Claude Bernard Lyon 1, Villeurbanne, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju\u0308rg A.","family":"Gasser","sequence":"additional","affiliation":[{"name":"4Novartis Institutes for Biomedical Research, Basle, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Castronovo","sequence":"additional","affiliation":[{"name":"3Metastasis Research Laboratory, University of Lie\u0300ge, Lie\u0300ge, Belgium; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Green","sequence":"additional","affiliation":[{"name":"4Novartis Institutes for Biomedical Research, Basle, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"4Novartis Institutes for Biomedical Research, Basle, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Cle\u0301zardin","sequence":"additional","affiliation":[{"name":"1Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale, UMR 664, IFR62, Lyon, France;"},{"name":"2Universite\u0301 Claude Bernard Lyon 1, Villeurbanne, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,10,17]]},"reference":[{"key":"2022061623184715700_B1","doi-asserted-by":"crossref","unstructured":"Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer\u20082004; 11: 207\u201324.","DOI":"10.1677\/erc.0.0110207"},{"key":"2022061623184715700_B2","doi-asserted-by":"crossref","unstructured":"Mundy GR. Metastasis to bone: causes, consequences, and therapeutic opportunities. Nat Rev Cancer\u20082002; 2: 584\u201393.","DOI":"10.1038\/nrc867"},{"key":"2022061623184715700_B3","unstructured":"Bendre SM, Gaddy-Kurten D, Mon-Foote T, et al. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res\u20082002; 62: 5571\u20139."},{"key":"2022061623184715700_B4","doi-asserted-by":"crossref","unstructured":"Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell\u20082003; 3: 537\u201349.","DOI":"10.1016\/S1535-6108(03)00132-6"},{"key":"2022061623184715700_B5","doi-asserted-by":"crossref","unstructured":"Hiraga T, Myyoui A, Choi ME, Yoshikawa H, Yoneda T. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-\u03b2 enhances bone metastases in breast cancer. Cancer Res\u20082006; 66: 2067\u201373.","DOI":"10.1158\/0008-5472.CAN-05-2012"},{"key":"2022061623184715700_B6","doi-asserted-by":"crossref","unstructured":"Boucharaba A, Serre CM, Gre\u0300s S, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest\u20082004; 114: 1714\u201325.","DOI":"10.1172\/JCI200422123"},{"key":"2022061623184715700_B7","doi-asserted-by":"crossref","unstructured":"Teitelbaum SL. Bone resorption by osteoclasts. Science\u20082000; 289: 1504\u20138.","DOI":"10.1126\/science.289.5484.1504"},{"key":"2022061623184715700_B8","doi-asserted-by":"crossref","unstructured":"Saftig P, Hunziker E, Wehmeyer O, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A\u20081998; 95: 13453\u20138.","DOI":"10.1073\/pnas.95.23.13453"},{"key":"2022061623184715700_B9","doi-asserted-by":"crossref","unstructured":"Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A\u20082006; 103: 7829\u201334.","DOI":"10.1073\/pnas.0601643103"},{"key":"2022061623184715700_B10","doi-asserted-by":"crossref","unstructured":"Rondeau JM, Bitsch F, Bourgier E, et al. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. Chem Med Chem\u20082006; 1: 267\u201373.","DOI":"10.1002\/cmdc.200500059"},{"key":"2022061623184715700_B11","unstructured":"Grabowska UB, Chambers TJ, Shiroo M. Recent developments in cathepsin K inhibitor design. Curr Opin Drug Discovery Dev\u20082005; 8: 619\u201330."},{"key":"2022061623184715700_B12","unstructured":"Littlewood-Evans AJ, Bilbe G, Bowler WB, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res\u20081997; 57: 5386\u201390."},{"key":"2022061623184715700_B13","unstructured":"Grosios K, Altmann E, Gasser JA, Stumm M, Zimmermann J. Efficacy of the bisphosphonate Zometa and the selective cathepsin K inhibitor AFG495 administered alone or in combination in a murine xenograft model of breast cancer cell induced osteolysis. Proc Am Assoc Cancer Res\u20082005; 46: Abs2910."},{"key":"2022061623184715700_B14","doi-asserted-by":"crossref","unstructured":"Pe\u0301cheur I, Peyruchaud O, Serre CM, et al. Integrin \u03b1v\u03b23 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J\u20082002; 16: 1266\u20138.","DOI":"10.1096\/fj.01-0911fje"},{"key":"2022061623184715700_B15","doi-asserted-by":"crossref","unstructured":"Peyruchaud O, Serre CM, NicAmhlaoibh R, Fournier P, Cle\u0301zardin P. Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity. J Biol Chem\u20082003; 278: 45826\u201332.","DOI":"10.1074\/jbc.M309024200"},{"key":"2022061623184715700_B16","doi-asserted-by":"crossref","unstructured":"Daubine\u0301 F, Le Gall C, Gasser J, Green J, Cle\u0301zardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst\u20082007; 99: 322\u201330.","DOI":"10.1093\/jnci\/djk054"},{"key":"2022061623184715700_B17","doi-asserted-by":"crossref","unstructured":"Brubaker KD, Vessella RL, True LD, Thomas R, Corey E. Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Min Res\u20082003; 18: 222\u201330.","DOI":"10.1359\/jbmr.2003.18.2.222"},{"key":"2022061623184715700_B18","doi-asserted-by":"crossref","unstructured":"Delaisse\u0301 JM, Andersen TL, Engsig MT, Henriksen K, Troen T, Blavier L. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclast activities. Microsc Res Techniq\u20082003; 61: 504\u201313.","DOI":"10.1002\/jemt.10374"},{"key":"2022061623184715700_B19","doi-asserted-by":"crossref","unstructured":"Everts V, Korper W, Hoeben KA, et al. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Min Res\u20082006; 21: 1399\u20131408.","DOI":"10.1359\/jbmr.060614"},{"key":"2022061623184715700_B20","doi-asserted-by":"crossref","unstructured":"Yeung F, Law WK, Yeh CH, et al. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem\u20082002; 277: 2468\u201376.","DOI":"10.1074\/jbc.M105947200"},{"key":"2022061623184715700_B21","doi-asserted-by":"crossref","unstructured":"Barnes GL, Hebert KE, Kamal M, et al. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res\u20082004; 64: 4506\u201313.","DOI":"10.1158\/0008-5472.CAN-03-3851"},{"key":"2022061623184715700_B22","doi-asserted-by":"crossref","unstructured":"Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclasto-genesis and prevents prostate tumor growth in the bone. J Clin Invest\u20082001; 107: 1235\u201344.","DOI":"10.1172\/JCI11685"},{"key":"2022061623184715700_B23","unstructured":"Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res\u20082001; 61: 4432\u20136."},{"key":"2022061623184715700_B24","unstructured":"Yonou H, Kanomata N, Goya M, et al. Osteoprotegerin\/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic\/severe combined immunodeficient mice. Cancer Res\u20082003; 63: 2096\u2013102."},{"key":"2022061623184715700_B25","doi-asserted-by":"crossref","unstructured":"Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature\u20082006; 440: 692\u20136.","DOI":"10.1038\/nature04524"},{"key":"2022061623184715700_B26","unstructured":"Bauss F, Wagner M, Hothorn LH. Total administered dose of ibandronate determines its effect on bone mass and architecture in ovariectomized aged rats. J Rheumatol\u20082002; 29: 990\u20138."},{"key":"2022061623184715700_B27","unstructured":"Adami S, Supronik J, Hala T, et al. Effect of one year treatment with the cathesin-K inhibitor, balicatib, on bone mineral density in postmenopausal women with osteopenia\/osteoporosis. J Bone Min Res\u20082006; 21: Abs1085."},{"key":"2022061623184715700_B28","doi-asserted-by":"crossref","unstructured":"Cle\u0301zardin P, Ebetino FH, Fournier PGJ. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res\u20082005; 65: 4971\u20134.","DOI":"10.1158\/0008-5472.CAN-05-0264"},{"key":"2022061623184715700_B29","doi-asserted-by":"crossref","unstructured":"Kim SJ, Uehara H, Yazici S, et al. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res\u20082005; 65: 3707\u201315.","DOI":"10.1158\/0008-5472.CAN-04-3601"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/20\/9894\/2575859\/9894.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/20\/9894\/2575859\/9894.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T22:11:31Z","timestamp":1655417491000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/20\/9894\/533756\/A-Cathepsin-K-Inhibitor-Reduces-Breast-Cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,15]]},"references-count":29,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2007,10,17]]},"published-print":{"date-parts":[[2007,10,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-3940","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,15]]}}}